Eckert & Ziegler consensus picture on Tuesday, shares tracked against medtech peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:27.

Eckert & Ziegler (DE0005659700) sits in the European medtech and radiopharmaceuticals segment, with the shares listed in the TecDAX via the Xetra venue in Frankfurt. On Tuesday the focus is on the analyst consensus picture around the stock, with several data providers publishing updated valuation ranges and rating distributions for the German specialist in radioisotopes.

What the consensus data shows

Consensus pages such as MarketScreener and finanzen.net aggregate analyst views on Eckert & Ziegler, including target prices, ratings and fair value estimates, giving investors a compact overview of expectations. According to MarketScreener, there are currently several active analyst recommendations on the stock, with categories ranging from Buy and Outperform to Hold and Underperform, and the average target price positioned at a level that implies a moderate upside versus recent Xetra trading.

The distribution of ratings is balanced, with neither a clear majority of strong Buy recommendations nor a dominant cluster of Sell calls, which points to a cautious stance on the shares. On finanzen.net, the consensus page for Eckert & Ziegler likewise reports multiple research houses following the stock, showing individual target prices and rating wording that help investors gauge how the market perceives the company’s growth and margin profile in the context of its niche in radiopharmaceuticals.

Analyst houses and sector comparisons

While no major new rating change from global houses such as Goldman Sachs or UBS has been reported for Eckert & Ziegler in the very latest 24 hours, the broader coverage by German research firms like Baader Bank and Warburg Research continues to underpin the consensus. These houses typically assess the company’s exposure to medical and industrial radioisotopes, its capital expenditure plans and its ability to convert the order book into recurring revenues, feeding their conclusions into the aggregated consensus figures on platforms like MarketScreener.

Sector comparisons often place Eckert & Ziegler alongside peers in the medtech and healthcare technology space, such as Siemens Healthineers or Drägerwerk, which also operate in regulated, technology-heavy healthcare markets. Exchange portals including Deutsche Börse and Börse Frankfurt show Eckert & Ziegler within the TecDAX cohort, where volatility can be higher than in large-cap indices like the DAX, and consensus metrics therefore play a larger role for risk-aware retail investors who watch valuation multiples and earnings revisions closely.

The product behind the stock

Eckert & Ziegler generates a large share of its revenues from radioisotope-based products for medical imaging and cancer therapy, particularly within its Radiopharma segment. Typical offerings include sealed radioactive sources and kits used in nuclear medicine departments, supporting diagnostic procedures such as PET and SPECT as well as targeted radiotherapy applications in oncology.

Where the stock trades today

The Eckert & Ziegler shares (DE0005659700) trade on Xetra at around 45 euros in recent sessions, with Deutsche Börse quote data indicating TecDAX membership and a market capitalization in the mid-hundreds of millions of euros as of late June 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.